Whole‐exome sequencing and immunohistochemistry findings in von Hippel–Lindau disease. Issue 9 (17th July 2019)

• Record Type: Journal Article
• Authors: Guo, Xiaopeng; Gao, Lu; Hong, Xiafei; Guo, Dan; Di, Wenyu; Wang, Xiaoman; Xu, Zhiqin; Xing, Bing
• Is Part Of: Molecular genetics & genomic medicine. Volume 7:Issue 9(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-17
• Subjects: hemangioblastoma -- phospho‐S6 ribosomal protein -- VHL gene -- von Hippel–Lindau disease -- whole‐exome sequencing; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.880
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Background: von Hippel–Lindau (VHL) disease has a hereditary, autosomal dominant pattern, and multiple tumors can develop in multiple organs of a single patient. However, the exact mechanisms of tumorigenesis are unclear, and further studies are needed to clarify whether the same signaling pathways are involved in different VHL‐related tumors. Methods: Whole‐exome sequencing (WES) of tumor and paired peripheral blood samples were performed for a VHL disease pedigree. A bioinformatics analysis was conducted to identify candidate somatic single‐nucleotide variants (SNVs) present in all tumor tissues. Sanger sequencing was then used to validate the SNVs identified using WES. Immunohistochemistry was performed to analyze components of the mTOR pathway, which was abnormally activated in tumor tissues. Results: Two hemangioblastomas and two renal cell carcinomas were sequenced. The bioinformatics analysis revealed a VHL somatic variant in all tumors; no other SNV was detected. Immunohistochemistry showed the abnormal expression of the phospho‐S6 ribosomal protein in the hemangioblastomas, but not in the renal clear cell carcinomas. Conclusion: Except for a SNV in the VHL gene, no other somatic SNVs were detected using WES. The phospho‐S6 ribosomal protein in the mTOR pathway is a potential target in VHL‐related cerebellum hemangioblastomas. Abstract : Whole‐exome sequencing of a VHL pedigree with peripheral blood and tumor tissue was performed. No somatic point mutations, except for the VHL gene, that cause VHL‐related tumor occurrence were recognized. Immunohistochemistry of the tumors showed that phospho‐S6 ribosomal protein in the mTOR pathway could be a potential target in VHL‐related cerebellum hemangioblastomas.